Browse by category

The first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in Ascletis Pharma’s US...

Ring-augmented RYGB (raRYGB) with a MiniMizer Ring in patients with BMI≥50kg/m2, results in significant weight loss and improvements in...

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

An International panel of experts has published 43 statements on the nature, terminology and mechanisms of action of metabolic and...

Bile acid diversion in Roux-en-Y gastric bypass (RYGB) reduces colorectal tumour growth and metastasis independent of weight loss,...

Protagonist Therapeutics has selected PN-477 a novel oral peptide - PN-477o with once-daily dosing, high potency and activation of...

China's National Medical Products Administration (NMPA) has approved Innovent Biologics’ mazdutide, a first-in-class dual glucagon...

Qaelon Medical has announced the formation of its Data Advisory Board (DAB) dedicated exclusively to data-driven detection, prevention...

A new potential drug lowers blood sugar and increases fat burning without negatively affecting appetite or muscle mass, according to a...

Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to...